for you, Thank Thank David. joining you us evening. this everyone
We and right new have initiatives product launches exciting motion now. in number of a
of So an excited all you provide to update today. I'm
were December. knew a an With to orphan in year. with our first I'd excited phase last would great and the We in an the in start our now we our four to product very business week, for we this But like I'll with occurred acquired carglumic recent of drug submitted additional been fit of clearly company. important that the be product expected be touch which launch approved when launch was It late products it quarters. have this and FDA today. acid, and coming commercial six and launch to of each them have Rezipres products we launched on
the report Although, trending we are ahead only initial months to pleased that three into well we of projections launch. I'm our for launch, are
of body in levels is only used the and generic can and elevated Carbaglu, ammonia patients which in treat adult of the million. expensive for the $X product of most is The to many the treatments is treatment cost Our exceed one first of world.
a from patients, So welcome cost payers a and professionals. received has lower healthcare reception alternative
are we branded the product fact brand refrigeration, advantages while including actually in has does a bioequivalent Although, fully product the does. generic, product, not product our over our require substitutable the
Additionally, benefit. our product And shelf product. after they labeling be for we to heard branded that patients life to has be already expect our a to shortly versus opening find XX-day updated that. this very valuable the We've from a reflect XX-days
the drive try often and discounting products. in sales discounts has to than through at product, sending product detail to physicians pricing your rather price trying Our by especially a on our instigate groups requesting directly adoption patient with massive strategy war to actively for payers. volumes with aggressive drugs been advocacy conferences to to exchange medical force, orphan Payers generic
market. XX% pursuing market Carbaglu million short-term believe We more will and than ability in the capture the and engage of pricing not is this our be market long-term use market to XX% are $XX revenue goal we to a an to product, and groups sales our force the of to long-term in we not economics. at talk our need Given in games. We advantages us the patient destroying believe of do to the for aggressive advocacy to is interested these US about cost attractive wins annually, directly believe the physicians,
December to have the and couple did very see the this of the now so impact seen year. that in added throughout have from would we in are of product revenue But we first patients year. months, the today. XXth, our an reporting significant the already expect the by we it of the on quarter first product by encouraged we adoption the goal are not results can launched the believe we quarter, reach have end fourth starting on quarter We second We we
Now drivers to XXXX. other turning for
will is adrenal our insufficiency the indicated grow orphan ALKINDI be treatment primary patients. continue SPRINKLE, of in compared the which to drug for One in sales ALKINDI drivers QX. QX of to pediatric
can However, we co-promotion believe late which a is pace, with they year. initiated grow much at we Tolmar agreement a faster why last
promoting this days They in have We SPRINKLE as of higher already ALKINDI announce product to January. promoting are we the expanded to XX partnership now this now working prescriptions for Tolmar’s we rates sales trained seeing of and second force been XX% the of seen half was benefits recent appears reach. pleased significantly are be weeks. have and field, in almost the co-promotion starting fully in the new
As have able able a they number with in-person greater were do been our own. of significantly to doctors on we meetings expected, conduct to than
apparent achieve believe even of we ago and week come, partnership last steady will in set the by the record be more of We to on saw record Tolmar scripts. breaking highest ever as cadence to two habits. just weeks month fact, repeat far is visits change doctor's Tolmar prescribing In March required full for scripts, patient are the the is was that our new new track patient quarters often physicians be old that benefit to able to
are digital in to expanded extra an push the of campaign. the Tolmar’s reps, marketing implementing process addition we In sales from
will caregivers an new We of branding enhanced dosing. benefits directly have precision and about educating and the focus with patients on messaging
injection US products, for turn launch will was in hospital our The vast including formulation to product our still commercial than that manually be I Rezipres our Next, Rezipres. newest is is a in The must two majority and sold market ready-to-use ephedrine. over the own to administration. ephedrine XX%. diluted more concentrated market last the prior form grew XX of year million of
of launch will we expect ready-to-use of convert the of Rezipres ultimately, the to We majority product the and help ready-to-use. accelerate adoption believe the market to
seen to to commercialize Rezipres a strong are optimistic interest XGen we drug with has the about initial and indicated injectable from customers, already company have that partnered XGen leading opportunity. We they've Pharmaceuticals, ampule. a us
Our Biorphen increased see hospital ampule product other continues adoption commercial quarter. to every
once below vial we the pleased and good. we presentation, Biorphen Rezipres working the to say and believe both we and I'm well of that data vials registration is late into initial are why is the convert opportunity what it occurred still formats. looks of year vial products aggressively is which last manufacturing to to at However, both convert batches levels the
to this end the year. waiting a vials both allow submit submitted launch just final time in in for But We prior which the are them the points to could order expect quarter, of data supplements. approval second stability on of before the be
balance. our -- requested our included In our partner believe received to triggered royalty of the payment Azurity launch product. a receive was payment we our in in cash liquid it it the recognized results The to and pharmacists, royalty our we a product. so topiramate will so as was us product demand cash payment had early $X to million market revenue and $X royalty a the products. was The most on opportunity and for the receive solution our We not segment, launched there's Pharmaceuticals significant be from but we in oral topiramate sales now million was year-end single January, actual December. digit QX achieved, large when found EPRONTIA, Turning oral and
the commercial bringing inspect pipeline to the we've front, In COVID-related all on that Suspension, made was of and unable last UK-based Oral products advance site due closer Zonisamide the to FDA we've because progress addition to the been held to this product continued restrictions. our up them is to approval this approval. had summer travel manufacturing
took completed. coming we from share hope receive believe in should have time, launch with application. from weeks the The of that to action FDA you million Azurity. approve target another and to not approval been date it a has but and this of $X January However, the the at Zonisamide or trigger allow end place received months. decision successful a to Unfortunately, us inspection It the a would payment to at the FDA was inspection product the new we we
Secondly, Lamotrigine.
submitted $X ongoing this trial launch so and questions I to Delaware to also the application for been Lamotrigine Our approval date of FDA IV later is in May normal. response results now addressed target XXXX. the trial, study call believe this the fully I human in actually would assigned a payment from response us. million letter. the am the The action And trigger The week. partner paragraph than Cysteine, the appreciate flexibility our the has all of hold the attending of quarter. everyone's new fourth Cysteine a FDAs completed and We complete factor
years now, product working been We than feel manufacturing before innovator's issue same ever been Exela format strongly XX more project. should partner has the the patents on as continue never for the Cysteine that in the to same began well our
in next have not second half decision, approval the timeline application and tentative to a to our early which the the receive lawyers While from responded application, this receive month. for allow expect FDA it requests judge's the do we year. believe, minor our we should our We final of to as as
against we innovators successfully exclusivity, patents. XXX if days generic first overturn the As be we their million of annually. the to market file $XX more The innovator, than is NDA should to entitled
the we prevail be if this launch would to So a product. able and opportunity, significant are
dehydrated Finally, alcohol.
addressing and and comments us an have response providing on with held resubmission to the in anticipated wants the approval the our increased in gave We but that working a the actively fourth and in us originally FDAs FDA quarter taking up exactly see them requests, those the wrapped than weeks. fully FDA meeting agency to points the received expect we and dialogue their address with is feedback what regarding wanted are We coming confidence the the on this that to longer address the a CRL. to application are with little
of in to products is that we the as inflection an it and our think point in are we exciting work launch develop. hard history so all time I undeniable, that these most important we
we Our by path goal to do including a so, million for significant to milestones injection. launching in and upside we Biorphen, million profitability successful revenue can product by and the of at the worth we on in of our sales of this carglumic plus alcohol of remains second year items acid or the We including achieve number least Cysteine the believe, And of the Rezipres of outcome Azurity, from launch achieve year. $XX our believe are a potentially trends of litigation materialize vial, end dehydrated receiving half this of the from year, $XX Alkindi. recent given launch strong sustained that could us approval and launch
Wilson? I So over financial now with to results. to our will discuss it turn Wilson that,
